CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg): A Triple‑Pathway Tool for Advanced Growth Hormone Research

If your research delves into the complex neuroendocrine regulation of the growth hormone (GH) axis, the CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg) offers a uniquely comprehensive experimental platform. This 9 mg formulation combines three well‑characterised GH secretagogues—CJC-1295 (Mod GRF 1-29), a modified GHRH analogue; Ipamorelin, a selective ghrelin receptor agonist; and GHRP-2, a potent growth hormone‑releasing peptide—each acting through distinct yet complementary mechanisms at the pituitary and hypothalamic levels.

CJC-1295 provides the primary stimulus to initiate GH synthesis by activating the classical GHRH receptor pathway. Ipamorelin and GHRP-2, meanwhile, engage the ghrelin/GHS‑R1a receptor system through different binding modes. By simultaneously targeting two major regulatory axes that converge at the pituitary, this blend allows researchers to model the synergistic interplay that governs GH pulsatility, providing deeper insight into the circuits that regulate endocrine signalling, metabolic homeostasis, and tissue repair.

At Wuhan Top Miracle Peptides, we supply high‑purity CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg) to research institutions and wholesale buyers across the United Kingdom, France, Germany, Spain, Sweden, Italy, and the USA. Every batch is lyophilised, HPLC‑verified to ≥98% purity, and accompanied by a Certificate of Analysis (COA), ensuring your investigations into GH regulation, IGF‑1 signalling, and metabolic research begin with uncompromising quality.

What Is the CJC-1295 & Ipamorelin & GHRP‑2 Blend and How Does It Work?

To fully appreciate the research potential of the CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg), it is essential to understand the distinct yet convergent mechanisms of its three components.

CJC-1295 (Mod GRF 1-29): The Stabilised GHRH Analogue

CJC-1295 (Mod GRF 1-29), also referred to as CJC-1295 without DAC, is a modified analogue of growth hormone‑releasing hormone (GHRH). It is a 29‑amino‑acid peptide with four amino acid substitutions that enhance its activity and render it resistant to proteolytic degradation. Unlike CJC‑1295‑DAC, which contains a drug affinity complex and has a half‑life of approximately 8 days, Mod GRF 1‑29 does not contain the DAC moiety and has a shorter half‑life.

As a GHRH analogue, CJC‑1295 acts on receptors in the anterior pituitary gland to stimulate the release of human growth hormone in a pulsatile manner. It has been shown to produce a 4‑fold increase in GH area under the curve over a 2‑hour period compared with native hGRF(1‑29). The version without DAC creates short, sharp GH spikes that more closely mimic natural physiology.

Ipamorelin: The Selective Ghrelin Receptor Agonist

Ipamorelin is a synthetic pentapeptide (Aib‑His‑D‑2‑Nal‑D‑Phe‑Lys‑NH₂) that was first described in a 1998 paper in the European Journal of Endocrinology as “the first selective growth hormone secretagogue”. Its defining pharmacological advantage is GH stimulation without elevating cortisol, ACTH, or prolactin, even at doses 200‑fold above the GH‑release ED₅₀.

Ipamorelin binds to COS‑7 cells expressing GHS‑R1a with a Ki of 63.4 nM. It stimulates GH release through selective activation of the ghrelin receptor (growth hormone secretagogue receptor, GHS‑R1a), inducing intracellular signalling cascades involving calcium mobilisation and protein kinase C.

GHRP-2: The Potent Growth Hormone‑Releasing Peptide

GHRP-2 (Pralmorelin, KP‑102) is a synthetic hexapeptide classified as part of the growth hormone secretagogue family. It has been widely explored for its strong binding affinity to the ghrelin receptor and its robust GH‑releasing activity. Like GHRP‑6, it acts through the same receptor and mechanism, stimulating GH release via phospholipase C and intracellular calcium flux.

GHRP-2 has been studied for its potential as a diagnostic agent for GH deficiency and its ability to stimulate growth in children. It also increases food intake in healthy men, consistent with its ghrelin‑mimetic properties.

Mechanism of Synergy: Triple‑Pathway Activation

The scientific rationale for combining CJC‑1295 (Mod GRF 1‑29), Ipamorelin, and GHRP‑2 lies in their convergent yet distinct mechanisms. When conceptualised as a blended research framework, these peptides invite investigation into how complementary properties might interact to yield distinct hormonal output patterns.

• CJC‑1295 (Mod GRF 1‑29) provides the primary “message” to initiate GH production by activating the classical GHRH receptor pathway, creating a sustained signalling foundation.

• Ipamorelin enhances the amplitude of that response by engaging the ghrelin/secretagogue receptor system with high selectivity, inducing a pulsatile release pattern of GH that may mimic endogenous rhythmicity.

• GHRP‑2 further reinforces the ghrelin receptor axis through its strong binding affinity and robust, transient GH‑releasing activity.

This triple‑pathway activation enables researchers to model the complex, multi‑stage process of GH regulation—from receptor‑level signalling to systemic metabolic outcomes. It has been hypothesised that CJC‑1295 may extend baseline receptor activity, creating a foundation upon which pulsatile stimulation from Ipamorelin and GHRP‑2 might operate. The transient peaks induced by ghrelin agonists, layered on sustained signalling from CJC‑1295, have been hypothesised to yield unique patterns of GH release that would not be achieved by any peptide alone.

Key Research Applications for the CJC-1295 & Ipamorelin & GHRP‑2 Blend (9mg)

The CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg) is a versatile tool with applications spanning several domains of endocrinological and metabolic research.

1. Growth Hormone Axis & Pituitary Function Studies

This blend provides a powerful model for investigating the hypothalamic‑pituitary‑somatotropic axis. Researchers can use it to study:

• The synergistic effects of GHRH and ghrelin pathway co‑activation on GH synthesis, storage, and pulsatile release.

• The distinct contributions of GHRH‑mediated and ghrelin‑mediated signalling to overall GH secretion.

• The dynamics of GH pulse amplitude and frequency in response to triple‑pathway stimulation.

• The potential for sustained baseline receptor activity layered with pulsatile peaks to yield unique hormonal output patterns.

2. Metabolic & Body Composition Research

By stimulating endogenous GH release through three pathways, this blend provides a model for studying the downstream metabolic effects of GH and IGF‑1 elevation. Research applications include:

• Metabolic Studies: Investigating the impact of GH modulation on energy balance, nutrient utilisation, and cellular metabolism.

• Lipid Metabolism: Exploring the role of GH in lipolysis and fat metabolism.

• Body Composition: Studying how enhanced GH secretion may influence muscle development, recovery, and overall body composition.

• Adipose Tissue Distribution: Examining how both peptides might impact the distribution of adipose tissue through their impacts on growth hormone secretion.

3. Receptor Pharmacology & Signalling Research

The blend may offer a multifaceted research modality for probing endogenous growth hormone axis mechanics. Researchers can use it to:

• Investigate the complex interplay between the GHRH and ghrelin systems.

• Study the downstream signalling pathways activated by GHRH and ghrelin receptor co‑stimulation.

• Characterise dual‑GPCR signalling and second‑messenger outputs in the context of GH regulation.

• Explore receptor bias and systems‑level integration within the organism.

Chemical & Physical Specifications for CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg)

Accurate characterisation of the CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg) is essential for reproducible experimental design.

Note: The 9 mg mass represents the total peptide weight of the blend. The exact ratio of CJC‑1295 (Mod GRF 1‑29) to Ipamorelin to GHRP‑2 is determined by the formulation (contact for details). The blend is supplied in a single lyophilised vial.

Reconstitution & Handling Protocol for the CJC-1295 & Ipamorelin & GHRP‑2 Blend (9mg)

Proper reconstitution of the CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg) is critical for maintaining the structural integrity and biological activity of all three peptides.

Step 1 – Preparation

• Bring the sealed blend vial and your chosen diluent (sterile bacteriostatic water or sterile PBS, pH 5‑7) to room temperature. Condensation can degrade the lyophilised powder.

• Clean your work surface with 70% ethanol and lay out sterile syringes, alcohol wipes and a clean work mat.

Step 2 – Vial Sanitisation

• Wipe the rubber stopper of the blend vial with a fresh 70% ethanol wipe. Allow the alcohol to evaporate completely before piercing.

Step 3 – Reconstitution

• Draw your desired volume of diluent into a sterile syringe. A common starting concentration for research applications is 9 mg per 0.9 mL of diluent, yielding a 10 mg/mL total peptide concentration.

• Insert the needle and slowly inject the diluent against the inner glass wall. Do not spray directly onto the lyophilised powder.

• Gently swirl the vial until the solution is clear and fully dissolved. Do not shake vigorously, as shaking can cause denaturation.

Step 4 – Aliquoting & Storage

• Immediately after dissolution, aliquot the reconstituted peptide blend into single‑use sterile vials.

• Store aliquots at –20°C. Avoid repeated freeze‑thaw cycles.

• Once thawed, store at 2‑8°C and use within a short period.

Concentration Reference Table for CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg)

Adjust diluent volume based on your experimental requirements. The exact concentration of each individual peptide within the blend is determined by the formulation’s component ratio.

Storage & Stability Guidelines for CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg)

Why Choose Wuhan Top Miracle Peptides for the CJC-1295 & Ipamorelin & GHRP‑2 Blend?

As an authentic licensed peptide supplier based in the United Kingdom, we supply the CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg) and a wide range of research‑grade compounds under rigorous quality assurance protocols, fully aligned with Google’s E‑E‑A‑T standards (Experience, Expertise, Authoritativeness, Trustworthiness).

• Verified Purity: Independent HPLC analysis with purity guaranteed ≥98% for each component, every batch.

• GMP‑Compliant Manufacturing: All peptides are synthesised under strict quality control conditions.

• Full Traceability: Batch‑specific Certificates of Analysis (COA) are available for every order.

• Wholesale Supply: We serve research institutions, laboratories, and wholesale buyers across the UK, EU, and USA with flexible volume pricing and reliable logistics.

• UK‑Based Regulatory Compliance: All products are supplied strictly as research‑grade chemicals for laboratory use only (RUO).

Researchers across the United Kingdom—including those at leading institutions in London, Cambridge, Oxford, Manchester, and Edinburgh—trust us for fast domestic delivery, transparent documentation and professional technical support.

FAQ: CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg)

What is the CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg)?
It is a research‑grade formulation combining CJC‑1295 (Mod GRF 1‑29, a modified GHRH analogue), Ipamorelin (a selective ghrelin receptor agonist), and GHRP‑2 (a potent growth hormone‑releasing peptide). It is used as a triple‑pathway tool to study growth hormone stimulation, IGF‑1 signalling, and metabolic research.

How does each component work?
CJC‑1295 (Mod GRF 1‑29) binds to GHRH receptors on pituitary somatotrophs, stimulating GH synthesis and release in a pulsatile manner. Ipamorelin binds to the growth hormone secretagogue receptor (GHS‑R1a), amplifying GH release without elevating cortisol, ACTH, or prolactin. GHRP‑2 acts through the same receptor, stimulating GH release via phospholipase C and intracellular calcium flux.

What is the proposed synergy between CJC‑1295, Ipamorelin, and GHRP‑2?
CJC‑1295 provides the primary stimulus to initiate GH production, while Ipamorelin and GHRP‑2 enhance the amplitude of that response through the ghrelin receptor axis. The sustained signalling from CJC‑1295, layered with pulsatile peaks from Ipamorelin and GHRP‑2, may yield unique patterns of GH release not achievable by any peptide alone.

What purity does your CJC‑1295 & Ipamorelin & GHRP‑2 Blend (9mg) meet?
Each component is tested to ≥98% purity by HPLC. A Certificate of Analysis (COA) is supplied with every order.

How should I reconstitute this peptide blend?
Reconstitute with sterile bacteriostatic water or sterile PBS (pH 5‑7). Allow the vial to reach room temperature, then slowly inject the diluent against the inner glass wall and swirl gently. Do not shake.

How should I store reconstituted peptide blends?
Reconstituted blends should be stored at 2‑8°C for short‑term use. For longer storage, aliquot immediately into single‑use vials and store at –20°C for up to 3 months. Avoid repeated freeze‑thaw cycles.

What is the difference between CJC‑1295 with DAC and without DAC?
CJC‑1295 without DAC (Mod GRF 1‑29) does not contain a drug affinity complex moiety and has a shorter half‑life than the DAC‑conjugated version. The version without DAC supports a more pulsatile release pattern that closely mimics natural physiology.

What distinguishes Ipamorelin from other GHRPs in research?
Ipamorelin is the first selective growth hormone secretagogue, stimulating GH without elevating cortisol, ACTH, or prolactin. Its high selectivity makes it a cleaner tool for studying GH dynamics compared to non‑selective secretagogues.

Is this peptide blend legal to purchase in the UK for research?
Yes. This blend is a laboratory reagent sold for research use only (RUO). It is fully legal to purchase, possess, and use in the United Kingdom for legitimate in‑vitro or in‑vivo scientific research, provided it is not marketed with therapeutic claims.

Does Wuhan Top Miracle Peptides ship internationally?
Yes. We ship across the EU (France, Germany, Spain, Sweden, Italy) and to the USA from our UK warehouse. Wholesale pricing is available for bulk orders.

Wholesale CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg) Supply Across the UK and Europe

Wuhan Top Miracle Peptides supports wholesale peptide blend buyers in the United Kingdom and international markets.

We Support Enquiries From:

• United Kingdom
• France
• Germany
• Spain
• Sweden
• Italy
• USA
• Wider Europe

For larger blend enquiries, contact our team before ordering. This helps confirm stock, documentation, shipping options, component identity, blend ratio, DAC status, and buyer verification requirements.

Where to Source CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg) in the UK

If you are searching for where to source CJC Ipamorelin GHRP-2 Blend 9mg in the UK, Wuhan Top Miracle Peptides provides a simple professional enquiry process.

Professional Enquiry Process

1. Review the blend product details.
2. Check the current label and batch information.
3. Confirm whether the batch lists CJC-1295, Mod GRF 1-29, or another documented identity.
4. Confirm whether the CJC-related component includes DAC.
5. Confirm whether Ipamorelin is listed as a component.
6. Confirm whether GHRP-2 is listed as a component.
7. Ask about the total vial content and blend ratio.
8. Ask about COA and purity-related documentation.
9. Confirm sequence and salt form for each component where required.
10. Confirm your shipping country.
11. Discuss wholesale quantity requirements.
12. Complete buyer verification where required.
13. Place a professional enquiry with support from our team.

Bulk Peptides Page
Shipping & Returns Page
Contact Us Page
Shop Page
Quality / Compliance Page
Ipamorelin Product Page
GHRP-2 Product Page
Mod GRF 1-29 Product Page
Scientific or compound reference source
Scientific or compound reference source
Scientific or compound reference source
GOV.UK / MHRA
Google Search Central
ASA / CAP Code Section 12

From its innovative design as a triple‑pathway GH secretagogue blend to its well‑documented role in modelling the synergistic interplay between the GHRH and ghrelin systems, the CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg) provides a uniquely versatile platform for advanced endocrinological and metabolic research. Its ability to stimulate endogenous GH release through three distinct yet convergent pathways—supported by peer‑reviewed research published in PubMed and other authoritative journals—makes it a valuable addition to any laboratory investigating the GH/IGF‑1 axis. By choosing high‑purity, lab‑verified CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg) from Wuhan Top Miracle Peptides, you ensure that your research is built on a foundation of quality, reproducibility, and scientific integrity.

Ready to advance your research with the CJC-1295 (Mod GRF 1-29) & Ipamorelin & GHRP-2 Blend (9mg)? Browse our product catalogue, request a wholesale quote, or contact our support team today to discuss your laboratory’s specific needs. Place your order now and receive GMP‑grade research peptides delivered directly to your facility in the UK, EU, or USA.